{"id":3144,"date":"2015-02-09T07:30:00","date_gmt":"2015-02-09T07:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/uppgorelse-mellan-xvivo-och-vivoline\/"},"modified":"2015-02-09T07:30:00","modified_gmt":"2015-02-09T07:30:00","slug":"uppgorelse-mellan-xvivo-och-vivoline","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/uppgorelse-mellan-xvivo-och-vivoline\/","title":{"rendered":"Uppg\u00f6relse mellan XVIVO och Vivoline"},"content":{"rendered":"<\/p>\n<p><span>XVIVO Perfusion AB (publ) ingav ans\u00f6kan om st\u00e4mning med yrkande om r\u00e4tt till tre patent\/patentans\u00f6kningar som tillh\u00f6r Vivoline Medical AB (publ) och som avser uppfinningar gjorda av Stig Steen. XVIVO Perfusion och Vivoline har nu tr\u00e4ffat en uppg\u00f6relse inneb\u00e4rande bland annat att XVIVO Perfusion \u00e5terkallar sin talan vid Lunds tingsr\u00e4tt och ers\u00e4tter Vivoline f\u00f6r r\u00e4tteg\u00e5ngskostnader med ett belopp om cirka 1,6 miljoner kronor, som kommer belasta f\u00f6rsta kvartalet 2015. Genom uppg\u00f6relsen \u00e4r parternas mellanhavanden i anledning av tvisten slutligt reglerade.<\/span><\/p>\n<\/p>\n<p><span>Uppg\u00f6relsen p\u00e5verkar inte XVIVO Perfusions nuvarande verksamhet och strategi. Bolagets egna produkter STEEN Solution\u2122, som skyddas av beviljade patent som l\u00f6per till \u00e5r 2021 (i USA 2022), och Perfadex<sup>\u00ae<\/sup> omfattas inte av den bakomliggande tvist som uppg\u00f6relsen g\u00e4ller.<\/span><\/p>\n<\/p>\n<p><span>G\u00f6teborg 9 februari 2015<\/span><br \/><span> XVIVO Perfusion AB (publ)<\/span><\/p>\n<div class=\"mfn-footer\">\n<p><span>F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n<p><span>Christoffer Rosenblad, CFO, tel: 031-788 21 59, e-post: <a href=\"mailto:christoffer.rosenblad@xvivperfusion.com\" rel=\"nofollow\">christoffer.rosenblad@xvivoperfusion.com<\/a><br \/>F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, <a href=\"http:\/\/www.xvivoperfusion.com\" rel=\"nofollow\">www.xvivoperfusion.com<\/a><\/span><\/p>\n<p><span>XVIVO Perfusion\u00a0\u00e4r skyldigt att offentligg\u00f6ra informationen i detta pressmeddelande enligt lagen om v\u00e4rdepappersmarknaden och\/eller lagen om handel med finansiella instrument. Informationen l\u00e4mnades f\u00f6r publicering den\u00a09 februari 2015 kl. 08:30.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>XVIVO Perfusion AB (publ) ingav ans\u00f6kan om st\u00e4mning med yrkande om r\u00e4tt till tre patent\/patentans\u00f6kningar som tillh\u00f6r Vivoline Medical AB&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3144","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Uppg\u00f6relse mellan XVIVO och Vivoline - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/uppgorelse-mellan-xvivo-och-vivoline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Uppg\u00f6relse mellan XVIVO och Vivoline - XVIVO\" \/>\n<meta property=\"og:description\" content=\"XVIVO Perfusion AB (publ) ingav ans\u00f6kan om st\u00e4mning med yrkande om r\u00e4tt till tre patent\/patentans\u00f6kningar som tillh\u00f6r Vivoline Medical AB...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/uppgorelse-mellan-xvivo-och-vivoline\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/uppgorelse-mellan-xvivo-och-vivoline\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/uppgorelse-mellan-xvivo-och-vivoline\\\/\",\"name\":\"Uppg\u00f6relse mellan XVIVO och Vivoline - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2015-02-09T07:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/uppgorelse-mellan-xvivo-och-vivoline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/uppgorelse-mellan-xvivo-och-vivoline\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/uppgorelse-mellan-xvivo-och-vivoline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Uppg\u00f6relse mellan XVIVO och Vivoline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Uppg\u00f6relse mellan XVIVO och Vivoline - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/uppgorelse-mellan-xvivo-och-vivoline\/","og_locale":"en_US","og_type":"article","og_title":"Uppg\u00f6relse mellan XVIVO och Vivoline - XVIVO","og_description":"XVIVO Perfusion AB (publ) ingav ans\u00f6kan om st\u00e4mning med yrkande om r\u00e4tt till tre patent\/patentans\u00f6kningar som tillh\u00f6r Vivoline Medical AB...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/uppgorelse-mellan-xvivo-och-vivoline\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/uppgorelse-mellan-xvivo-och-vivoline\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/uppgorelse-mellan-xvivo-och-vivoline\/","name":"Uppg\u00f6relse mellan XVIVO och Vivoline - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2015-02-09T07:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/uppgorelse-mellan-xvivo-och-vivoline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/uppgorelse-mellan-xvivo-och-vivoline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/uppgorelse-mellan-xvivo-och-vivoline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Uppg\u00f6relse mellan XVIVO och Vivoline"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}